公开(公告)号：US11903951B2

公开(公告)日：2024-02-20

申请号：US15612454

申请日：2017-06-02

申请人： M et P Pharma AG

发明人： Claudia Mattern

IPC分类号： A61K31/56 ,  A61K47/44 ,  A61K31/57 ,  A61K9/06 ,  A61K47/02 ,  A61K31/568 ,  A61K31/4458 ,  A61K31/381 ,  A61K31/165 ,  A61K31/496 ,  A61K31/13 ,  A61K47/69 ,  A61K9/00 ,  A61K9/16 ,  A61K9/50

CPC分类号： A61K31/56 ,  A61K9/0043 ,  A61K9/06 ,  A61K31/13 ,  A61K31/165 ,  A61K31/381 ,  A61K31/4458 ,  A61K31/496 ,  A61K31/568 ,  A61K31/57 ,  A61K47/02 ,  A61K47/44 ,  A61K47/6923 ,  A61K9/1611 ,  A61K9/1635 ,  A61K9/5015

摘要： Described herein are nasal pharmaceutical compositions comprising a porous excipient and an active agent, wherein the active agent is loaded onto a surface of the porous excipient located inside pores of the porous excipient, and wherein the composition is adapted for nasal administration. Also described herein are methods of making and using nasal pharmaceutical compositions.

公开(公告)号：US20210283143A1

公开(公告)日：2021-09-16

申请号：US17157337

申请日：2021-01-25

申请人： M ET P PHARMA AG

发明人： Claudia MATTERN ,  Elisabeth TRAIFFORT ,  Michael SCHUMACHER

IPC分类号： A61K31/568 ,  A61K9/00 ,  A61K31/4436 ,  A61K31/506

摘要： Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.

公开(公告)号：US10729646B2

公开(公告)日：2020-08-04

申请号：US16016335

申请日：2018-06-22

申请人： M et P Pharma AG

发明人： Claudia Mattern

IPC分类号： A61K9/00 ,  A61K47/44 ,  A61K33/00 ,  A61K47/02 ,  A61K9/06 ,  A61K47/14 ,  A61P37/08 ,  A61P39/00 ,  A61P29/00 ,  A61P39/06 ,  A61K45/06 ,  A61K47/26

摘要： Described herein are methods for reducing the risks of exposure to air pollutants, comprising nasally administering to a subject in need thereof a composition that counteracts the effects of one or more air pollutants, wherein the composition is adapted for nasal administration. In some embodiments the composition comprises an agent that binds to one or more air pollutants, wherein the agent comprises one or both of nonporous silicon dioxide and porous silicon dioxide and/or the composition provides a physical barrier between one or more air pollutants and internal nasal surfaces. Also described are nasal compositions comprising an agent comprising one or both of nonporous silicon dioxide and porous silicon dioxide, a lipophilic or partly lipophilic vehicle, and a surfactant, wherein the composition is adapted for nasal administration. The compositions also may comprise other agents, such as an immunosuppressant. Also described are methods of making and using the compositions.

公开(公告)号：US20180200203A1

公开(公告)日：2018-07-19

申请号：US15716337

申请日：2017-09-26

申请人： M ET P PHARMA AG

发明人： Claudia MATTERN

IPC分类号： A61K31/137 ,  A61K9/16 ,  A61K9/00 ,  A61K9/06 ,  A61K9/127

CPC分类号： A61K31/137 ,  A61K9/0043 ,  A61K9/06 ,  A61K9/127 ,  A61K9/1605

摘要： This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of the active ingredient in plasma and brain caused by sustained serum levels and/or direct or partly direct transport from nose to the brain.

公开(公告)号：US20200206244A1

公开(公告)日：2020-07-02

申请号：US16815969

申请日：2020-03-11

申请人： M ET P PHARMA AG

发明人： Claudia MATTERN ,  Elisabeth TRAIFFORT ,  Michael SCHUMACHER

IPC分类号： A61K31/568 ,  A61K31/506 ,  A61K31/4436 ,  A61K9/00

摘要： Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.

公开(公告)号：US11723911B2

公开(公告)日：2023-08-15

申请号：US17157337

申请日：2021-01-25

申请人： M ET P PHARMA AG

发明人： Claudia Mattern ,  Elisabeth Traiffort ,  Michael Schumacher

IPC分类号： A61K31/56 ,  A61K31/381 ,  A61K31/565 ,  A61K31/4545 ,  A61K31/568 ,  A61K9/00 ,  A61K31/4436 ,  A61K31/506

CPC分类号： A61K31/568 ,  A61K9/0043 ,  A61K31/4436 ,  A61K31/506

摘要： Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.

公开(公告)号：US10898495B2

公开(公告)日：2021-01-26

申请号：US16815969

申请日：2020-03-11

申请人： M ET P PHARMA AG

发明人： Claudia Mattern ,  Elisabeth Traiffort ,  Michael Schumacher

IPC分类号： A61K31/56 ,  A61K31/381 ,  A61K31/565 ,  A61K31/545 ,  A61K31/568 ,  A61K9/00 ,  A61K31/4436 ,  A61K31/506

摘要： Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.

公开(公告)号：US20180008615A1

公开(公告)日：2018-01-11

申请号：US15612454

申请日：2017-06-02

申请人： M et P Pharma AG

发明人： Claudia Mattern

IPC分类号： A61K31/56 ,  A61K9/00 ,  A61K47/44

CPC分类号： A61K31/56 ,  A61K9/0043 ,  A61K9/06 ,  A61K9/1611 ,  A61K9/1635 ,  A61K9/5015 ,  A61K31/13 ,  A61K31/165 ,  A61K31/381 ,  A61K31/4458 ,  A61K31/496 ,  A61K31/568 ,  A61K31/57 ,  A61K47/02 ,  A61K47/44 ,  A61K47/6923

摘要： Described herein are nasal pharmaceutical compositions comprising a porous excipient and an active agent, wherein the active agent is loaded onto a surface of the porous excipient located inside pores of the porous excipient, and wherein the composition is adapted for nasal administration. Also described herein are methods of making and using nasal pharmaceutical compositions.

公开(公告)号：US20220062165A1

公开(公告)日：2022-03-03

申请号：US17047542

申请日：2019-04-16

申请人： M et P Pharma AG

发明人： Claudia Mattern

IPC分类号： A61K9/00 ,  A61K31/573 ,  A61K9/06 ,  A61P25/00

摘要： This invention relates to methods of increasing activity of the neurotransmitter acetylcholine in specific brain regions to treat diseases or disorders associated with reduced acetylcholine activity. In particular, the methods relate to intranasal administration of pregnenolone in only one nostril increasing acetylcholine activity only in the amygdala corresponding to this nostril, thus, providing ipsilateral increase of acetylcholine activity.

公开(公告)号：US09962394B2

公开(公告)日：2018-05-08

申请号：US15403627

申请日：2017-01-11

申请人： M et P PHARMA AG

发明人： Claudia Mattern

IPC分类号： A61K31/57 ,  A61K47/44 ,  A61K31/568 ,  A61K47/02 ,  A61K9/00 ,  A61K47/14

CPC分类号： A61K31/57 ,  A61K9/0043 ,  A61K9/06 ,  A61K31/568 ,  A61K47/02 ,  A61K47/14 ,  A61K47/44

摘要： This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained scrum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.